[ad_1]
The second dose of the one-time COVID vaccine caused a nine-fold increase in antibodies.
Based on interim data from two early trials, Johnson & Johnson (J&J) stated that its booster injection of the COVID-19 vaccine has greatly increased antibody levels.
The company said at a news conference on Wednesday that the second dose of the US company’s single-dose vaccine resulted in binding antibody levels that were 9 times higher than people’s levels 28 days after the first dose.
Unlike neutralizing antibodies that destroy viruses, binding antibodies will attach to the virus, but will not destroy the virus or prevent infection. Instead, they remind the immune system of its existence so that it can send white blood cells to destroy it.
When the new information was released, several countries, including the United States, had already Start to provide booster doses Since the Delta variant has spread and some vaccinated people have been infected with COVID-19, other vaccines are used for vulnerable individuals, including individuals with weakened immune functions.
There is no previous evidence to show the effect of booster doses of Johnson & Johnson vaccine.
In particular, consultants from the US Centers for Disease Control and Prevention (CDC) have been waiting for news on how to provide advice on how to provide advice to immunocompromised people who have received the Johnson & Johnson vaccine.
According to Johnson & Johnson, these studies show that participants aged 18-55 and those 65 years of age and older receiving lower booster doses have significantly increased conjugate antibody responses.
Research abstracts are being submitted to the preprint server MedRxiv before peer review.
The results were released before the long-awaited results of Johnson & Johnson’s large two-dose vaccine trial. A spokesperson said these results will be announced in the next few weeks.
In July, data published by Johnson & Johnson in the New England Journal of Medicine showed that the neutralizing antibodies produced by its vaccine remained stable 8 months after receiving a single dose of the vaccine.
“Through these new data, we also see that the booster dose of Johnson & Johnson’s COVID-19 vaccine further increases the antibody response of study participants who have previously received our vaccine,” Mathai Mammen, director of research and development of Johnson & Johnson’s Janssen Pharmaceutical Division, in a statement Said in.
“We look forward to discussing our potential strategy for Johnson & Johnson’s COVID-19 vaccine with public health officials, eight months or more after the main single-dose vaccine.”
Several scientists worry that people who are given the Johnson & Johnson vaccine need a booster.
A study conducted by a team from New York University found that a “large portion” of the blood samples of recipients who received Johnson & Johnson injections had low neutralizing antibodies against Delta and several other coronavirus variants.
Johnson & Johnson said the company is working with the CDC, the US Food and Drug Administration, the European Medicines Agency, the World Health Organization and other health authorities to provide booster injections.
[ad_2]
Source link